Involved in many disease pathologies, DUBs are attractive therapeutic targets
World-leading DUB platform translating scientific advances into transformative therapies
First-in-class small molecule DUB inhibitors developed in-house and with partners
Multiple in-house DUB inhibitor programs in the clinic or approaching clinical development
Mission Therapeutics is determined to make a positive impact on the lives of patients suffering from serious diseases including Parkinson’s Disease (PD) and other neuro-degenerative conditions, heart and kidney diseases, fibrosis, and rare mitochondria diseases, by developing first-in-class therapeutics that inhibit disease-associated deubiquitylating enzymes (DUBs).
Our lead candidates – MTX325 and MTX652 – aim to inhibit USP30, a DUB which can retard the essential cellular quality control process called mitophagy.
To hear our CEO discuss our technology, programs, recent progress and strategy, watch our Corporate Presentation.
Mission gains clearance from US FDA for Phase II trial of…